Genedata Strengthens TcLand Expression’s Research Informatics Infrastructure for Personalized Medicine
News Apr 09, 2009
Genedata has announced collaboration with TcLand Expression. As part of the collaboration, the Genedata Phylosopher® and Expressionist® biomarker discovery platforms will be integrated into TcLand Expression’s computational infrastructure.
TcLand Expression is pioneering work in the field of personalized medicine for transplantation and autoimmune diseases. The company is developing gene expression signatures in collaboration with health care professionals and patients worldwide. The Genedata Expressionist® and Phylosopher® platforms will serve as a scalable core infrastructure supporting interdisciplinary biomarker identification, validation and mode-of-action studies.
The platform will enable TcLand Expression’s researchers to take a cross-technology approach by using automated workflows and integrated analysis tools to streamline the research workflow, from experimental design through to final results.
“Genedata’s biomarker platform complements perfectly our existing clinical and sample management systems,” commented Alessandra Cervino DPhil, VP Biostatistics and Bioinformatics at TcLand Expression. “Genedata’s integrated solution combines the flexibility needed in our R&D processes with the automation, traceability and 21 CFR part 11 compliance needed in our clinical studies.”
“Genedata’s integrated solution fits in well with TcLand Expression’s quality commitment to our R&D,” stated Alain Huriez MD, Chairman and CEO of TcLand Expression.
"We are delighted that TcLand Expression, one of the innovators in the area of personalized medicine, has chosen our platform to address their computational requirements,” said Othmar Pfannes, CEO of Genedata. “This collaboration validates our strategy of delivering scalable and flexible research IT infrastructure solutions for biomarker discovery, monitoring and biological interpretation.”
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE